523 Davis Drive
Tel: (919) 495-4510
About Locus Biosciences
Locus Biosciences is a biotechnology company that develops CRISPR-engineered precision antibacterial products. Our CRISPR-Phage (“crPhage”) platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage. By selectively removing unwanted bacteria while leaving the many species of good bacteria intact, crPhage™ can address the growing set of diseases shown to be related to the human microbiome.
Co-Founder, CEO & Chairman of the Board: Paul Garofolo Co-Founder & CSO: Dave Ousterout, PhD
Chief Development Officer: Paul Kim, PhD
Senior Vice President, Business Development: Joseph Nixon, MBA
Vice President, Chemistry, Manufacturing, and Controls: Louise Hall
Co-Founder & Scienfic Advisor: Rodolphe Barrangou, PhD, MBA
Co-Founder & Scienfic Advisor: Charles Gersbach, PhD
Co-Founder & Scienfic Advisor: Chase Beisel, PhD
6 articles with Locus Biosciences
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen)
Under the terms of the deal, Janssen is paying Locus $20 million up front. Locus will be eligible for up to a total of $798 million in development and commercial milestones, as well as royalties on any product sales.
Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics
Acquisition significantly accelerates development of new products targeting antibiotic-resistant pathogens and microbiome indications
Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test for Pseudomonas Aeruginosa Infection
Once LBx-PA01 reaches the market, the test will ensure that the medication will be given to patients with the greatest opportunity to benefit from it, improving patient outcomes and reducing the overall cost of treatment.
RTIS Ventures led the round, with additional financing from notable institutional investors Tencent Holdings Limited, Abstract Ventures, and the North Carolina Biotechnology Center, among others.